The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Greenwich LifeSciences (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Jee Hyun Kim
Honoraria - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche; Roche; Sanofi
Consulting or Advisory Role - Bixink; Daiichi Sankyo/Astra Zeneca; Eisai; Everest Medicine; MSD; Roche; Yuhan
Research Funding - Eisai (Inst); Ono Pharmaceutical (Inst); Roche (Inst)
 
Natalja Eigeliene
Consulting or Advisory Role - Lilly O.
Research Funding - Lilly O.
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche
 
Dimitrios Mavroudis
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Sanofi
Travel, Accommodations, Expenses - Genesis Pharmaceuticals; Gilead Sciences
 
Dragos Mircea Median
Consulting or Advisory Role - MSD; Novartis
Speakers' Bureau - Accord Healthcare; AstraZeneca; GeneKor; Lilly O.; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly O.; Roche
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Heloisa Marconato
No Relationships to Disclose
 
Serhii Shevnia
No Relationships to Disclose
 
Ozgur Ozyilkan
No Relationships to Disclose
 
Juan Manuel Puig
Research Funding - Lilly O.
 
Catherine M. Shannon
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Lilly; Merck sharp and Dohme; Roche
Speakers' Bureau - Amgen; AstraZeneca; Gilead Sciences; GlaxoSmithKline; merk sharp & Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Maria Munoz
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Belén San Antonio
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Ran Wei
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Ontada/McKesson; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Stephen R. D. Johnston
Honoraria - AstraZeneca; Eisai; Lilly; Pfizer
Consulting or Advisory Role - Genzyme; Lilly; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst)
Expert Testimony - Novartis
 
Valentina Guarneri
Consulting or Advisory Role - Eisai; Exact Sciences; Gilead Sciences; Lilly; Merck Serono; MSD; Novartis; Olema Oncology
Speakers' Bureau - Amgen; AstraZeneca; GlaxoSmithKline; Lilly; Novartis
Research Funding - AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Roche (Inst); Synthon (Inst)
Expert Testimony - Lilly
Travel, Accommodations, Expenses - Gilead/Forty Seven